A survey of CMV prevention strategies after liver transplantation

J. Levitsky*, N. Singh, M. M. Wagener, V. Stosor, M. Abecassis, M. G. Ison

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

98 Scopus citations


The degree of variability in the use of CMV prevention strategies and choice of antiviral regimens among LT centers has not been previously investigated. An electronic survey on current CMV prevention strategies was sent to all US and Canadian LT centers. A total of 58 (53%) centers completed the survey. Most use CMV PCR for screening or diagnosis. Prophylaxis was the most common prevention strategy for all donor/recipient subtypes except D-/R- who often receive no prophylaxis. Prophylaxis was usually given for 3 months after LT with valganciclovir the most frequently used agent. In the small percentage of centers utilizing the preemptive approach, monitoring for CMV was typically performed with PCR for 3 months and valganciclovir was most frequently used for treatment of detectable CMV viremia. In conclusion, the majority of LT centers utilize CMV prophylaxis over other strategies. Valganciclovir is the most commonly used agent for both antiviral prophylaxis and treatment of CMV viremia in the preemptive approach.

Original languageEnglish (US)
Pages (from-to)158-161
Number of pages4
JournalAmerican Journal of Transplantation
Issue number1
StatePublished - Jan 2008


  • Cytomegalovirus (CMV)
  • Liver transplantation
  • Preemptive antiviral therapy
  • Prophylaxis

ASJC Scopus subject areas

  • Transplantation
  • Pharmacology (medical)
  • Immunology and Allergy


Dive into the research topics of 'A survey of CMV prevention strategies after liver transplantation'. Together they form a unique fingerprint.

Cite this